Loading...
XSWX
KURN
Market cap1.48bUSD
Dec 05, Last price  
30.64CHF
1D
-1.23%
1Q
19.13%
Jan 2017
70.48%
IPO
-99.27%
Name

Kuros Biosciences AG

Chart & Performance

D1W1MN
XSWX:KURN chart
P/E
—
P/S
15.79
EPS
—
Div Yield, %
—
Shrs. gr., 5y
16.72%
Rev. gr., 5y
96.78%
Revenues
76m
+125.11%
4,358,000724,00035,882,00019,723,0009,108,00022,349,0001,571,0001,100,0001,000,0001,000,0006,355,0001,061,000534,000715,0002,561,0004,039,00013,815,00017,986,00033,564,00075,555,000
Net income
-4m
L-72.93%
-28,480,000-34,552,000-6,875,000-26,009,000-24,826,000-1,454,000-18,779,000-9,216,000-30,826,000-34,026,0006,227,000-19,744,000-16,484,000-11,693,000-11,252,000-11,520,000-7,541,000-14,595,000-13,727,000-3,716,000
CFO
3m
P
-27,078,000-28,674,000-4,398,000-27,895,000-15,248,000-4,685,000-8,807,000-11,537,000-19,170,000-23,758,000-2,514,000-8,893,000-10,678,000-12,838,000-10,849,000-9,239,000-5,453,000-7,348,000-8,844,0003,140,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.
URL
http://www.kuros.ch/
IPO date
Oct 29, 2002
Employees
73
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT